Abstract
The capsule drug ring (CDR) is a reservoir and delivery agent, which is designed to be placed within the capsular bag during cataract surgery. Prototypes were manufactured by hot melt extrusion of Bionate II®, a polycarbonate urethane. The devices have been optimized using Avastin® as the drug of interest. In vitro biocompatibility was assessed with human lens epithelial cell (B-3), mouse macrophage (J774A.1) and mouse fibroblast (L-929) cell lines. Cell migration and proliferation were assessed after in vitro culture. Pro-inflammatory cytokines (i.e., MIP-1β, MIP-1α, MCP-1, IL-1β, TNF and TGF-β1) were quantified using cytometric bead array (CBA). Preliminary in vivo biocompatibility and pharmacokinetics testing has been performed in rabbits.
Highlights
Of the diseases that result in vision loss, those which affect the retina and retinal function are of particular research interest due to the resultant permanent loss of visual function for which there is noJ
While Lucentis is a prescription medicine for the treatment of Age-related macular degeneration (AMD), Avastin is being investigated as a lower-cost potential alternative therapy and is often used off-label for the clinical treatment of AMD [3]
Significant improvement can be made in patient health outcomes through the development of an extended release device
Summary
Of the diseases that result in vision loss, those which affect the retina and retinal function are of particular research interest due to the resultant permanent loss of visual function for which there is no. Current therapies restrict the progression of the disease, but due to limitations inherent in current pharmaceutical delivery modalities, cannot cure it [1,2,3,4,5]. Continuous or repeated treatment is an implication of this form of therapy. Age-related macular degeneration (AMD) is the leading cause of blindness and significant visual impairment in developed nations. There are 30 million worldwide cases of AMD; in the United States, there are over 2 million current cases of advanced AMD, with 200,000 new cases every year [3]. AMD is expressed in two principle forms
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
